ArticleLa Radiologia medica2025
Accuracy and safety of percutaneous CT-guided pancreatic biopsies.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the accuracy and safety of CT-guided percutaneous core-needle biopsies of pancreatic lesions suspected to be malignant based on MRI or CT scans. MATERIALS AND
methodsThis retrospective study analyzed CT-guided percutaneous biopsies of suspicious pancreatic lesions performed at our university hospital. Biopsy was performed using a 17G coaxial needle and an 18G core biopsy needle. Data on patient characteristics, lesions, procedures, and histologic results were recorded.
resultsA total of 90 patients (58.9% males, mean age 65 ± 12.2 years) underwent CT-guided percutaneous biopsies. The lesions had a mean size of 36.8 ± 12.2 mm and were predominantly located in the pancreatic head 61.1% (55/90). Technical success was achieved in all biopsies 100% (90/90). Most procedures 96.7% (87/90) were performed using direct access routes, while 3.3% (3/90) required indirect transhepatic or transgastric approaches. Among the biopsies, 65.6% (59/90) confirmed malignancy, with adenocarcinoma as the most common malignant subtype representing 55.6% (50/90) of all cases. The rate of non-malignant findings was 26.7% (24/90) including chronic pancreatitis at a rate of 5.6% (5/90) as well as pancreatic pseudocysts and pancreatic cystadenoma each at a rate of 2.2% (2/90), among others. A total of seven cases were identified as false negatives confirmed, but malignancy was later confirmed after re-biopsy or surgery. The initial diagnostic accuracy was 92.2% (83/90). The rate of major complications was 1.1% (1/90), and a total of two minor complications at a rate of 2.2% were observed.
conclusionThis study shows that CT-guided pancreatic biopsy is a safe procedure with high diagnostic accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.